David Esposito is an experienced healthcare executive and combat veteran. Prior to becoming the CEO of ONL Therapeutics, David built and scaled multiple healthcare companies that resulted in successful exits to strategic buyers (Armune BioScience sold to Exact Sciences (EXAS) in December 2017 and Phadia US/AB sold to Thermo Fisher Scientific (TMO) September 2011). David began his career with Merck & Co. Inc., as a sales representative and worked through various senior management positions. He led commercial strategy for the US Division and played a key role in Merck’s efforts to develop a new commercial model in the pharmaceutical industry.

David is a member of the board of directors for Shield Bio and AllerGenis. David has a B.S. in Civil Engineering from the United States Military Academy at West Point and an MBA from Syracuse University.